Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Ag Postfinance sold 236,155 shares of Cytori Therapeutics stock in a transaction on Friday, February 9th. The stock was sold at an average price of $0.34, for a total transaction of $80,292.70. Following the sale, the insider now directly owns 5,311,451 shares of the company’s stock, valued at approximately $1,805,893.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ag Postfinance also recently made the following trade(s):

  • On Tuesday, February 13th, Ag Postfinance sold 286,982 shares of Cytori Therapeutics stock. The stock was sold at an average price of $0.31, for a total transaction of $88,964.42.

Cytori Therapeutics Inc (NASDAQ:CYTX) opened at $0.36 on Thursday. Cytori Therapeutics Inc has a fifty-two week low of $0.22 and a fifty-two week high of $2.13.

Several hedge funds have recently made changes to their positions in CYTX. Vanguard Group Inc. grew its holdings in shares of Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares during the period. Sabby Management LLC grew its holdings in shares of Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares during the period. Finally, Perkins Capital Management Inc. grew its holdings in shares of Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares during the period. 10.82% of the stock is owned by institutional investors.

A number of analysts have commented on the stock. Maxim Group set a $4.00 target price on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Tuesday. Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://weekherald.com/2018/02/15/cytori-therapeutics-inc-cytx-major-shareholder-sells-80292-70-in-stock.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply